Thioredoxin-interacting protein seen as drug target

Pharmacological suppression of thioredoxin-interacting protein (TXNIP) may improve outcomes in many cardiovascular disease states and in diabetes, according to a paper published by Australian researchers.

It is likely that targeting TXNIP may rescue pancreatic beta-cells or cardiomyocytes from apoptosis in the presence of diabetes, much like ACE-inhibitors for early renal dysfunction, they say.

TXNIP is synthesized in response to increased blood sugar levels and abnormal wall stresses in blood vessels, and is implicated in many

Latest

Trending